Streetbeat News

Price Targets

SHAK

TD Cowen analyst Andrew Charles maintains a Market Perform rating on Shake Shack (NYSE:SHAK) and raises the price target from $67 to $75.

Portfolio Pulse from richadhand@benzinga.com

May 31, 2023 | 3:50 pm

SBUX

TD Cowen analyst Agnes Lim maintains an Outperform rating on Starbucks (NASDAQ:SBUX) but lowers the price target from $120 to $117.

Portfolio Pulse from richadhand@benzinga.com

May 31, 2023 | 3:48 pm

QSR

TD Cowen analyst Andrew Charles maintains an Outperform rating on Restaurant Brands Intl (NYSE:QSR) and raises the price target from $80 to $85.

Portfolio Pulse from richadhand@benzinga.com

May 31, 2023 | 3:47 pm

MCD

TD Cowen analyst Andrew Charles maintains an Outperform rating on McDonald's (NYSE:MCD) and raises the price target from $320 to $326.

Portfolio Pulse from richadhand@benzinga.com

May 31, 2023 | 3:46 pm

FWRG

TD Cowen analyst Andrew Charles maintains a Market Perform rating on First Watch Restaurant Gr (NASDAQ:FWRG) and raises the price target from $18 to $19.

Portfolio Pulse from richadhand@benzinga.com

May 31, 2023 | 3:44 pm

DPZ

TD Cowen analyst Andrew Charles maintains a Market Perform rating on Domino's Pizza (NYSE:DPZ) and lowers the price target from $350 to $330.

Portfolio Pulse from richadhand@benzinga.com

May 31, 2023 | 3:43 pm

HPE

Hewlett Packard Enterprise (HPE) stock is down after mixed Q2 results and weak Q3 guidance. Analysts from Susquehanna, Raymond James, and Credit Suisse have reiterated their ratings and adjusted price targets. HPE's Compute sales are expected to decline Y/Y until mid-2024, but growth in Intelligent Edge and AI could provide a favorable mix.

Portfolio Pulse from Anusuya Lahiri

May 31, 2023 | 3:41 pm

CSIQ

Roth MKM analyst Justin Clare reiterates a Buy rating on Canadian Solar (NASDAQ:CSIQ) and raises the price target from $55 to $70.

Portfolio Pulse from Benzinga Newsdesk

May 31, 2023 | 3:31 pm

PDD

In the last quarter, PDD Holdings (NASDAQ:PDD) received 8 bullish, 3 somewhat bullish, and 2 indifferent analyst ratings. The company's average 12-month price target is $96.0, representing an 8.42% decrease from the previous average of $104.83.

Portfolio Pulse from Benzinga Insights

May 31, 2023 | 3:10 pm

CLDX

In the last 3 months, 4 analysts have offered 12-month price targets for Celldex Therapeutics (NASDAQ:CLDX), with an average price target of $68.25, up 24.09% from the previous average of $55.00. The company has received 3 bullish and 1 somewhat bullish ratings.

Portfolio Pulse from Benzinga Insights

May 31, 2023 | 3:09 pm